Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
157 studies found for:    dengue
Show Display Options
Rank Status Study
61 Completed Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
Condition: Dengue Hemorrhagic Fever
Interventions: Biological: rDEN1delta30;   Biological: rDEN2/4delta30(ME);   Biological: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
62 Completed A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
Condition: Dengue
Intervention: Biological: Live attenuated tetravalent dengue vaccine
63 Completed Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults
Condition: Dengue Fever
Interventions: Biological: rDEN1delta30;   Biological: Placebo
64 Completed Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
Condition: Dengue Fever
Interventions: Biological: rDEN2/4delta30(ME) Vaccine;   Biological: Placebo
65 Unknown  Dengue Seroprevalence Study in Blood Donors in the French West Indies
Conditions: Blood Donors;   Dengue
Intervention: Other: Biological sample collection
66 Completed Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Diseases
Interventions: Biological: Chimeric dengue serotype 1, 2, 3, and 4;   Biological: Pneumococcal polysaccharide vaccine
67 Completed
Has Results
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Condition: Dengue Fever
Interventions: Drug: TDV Liquid Formulation 1;   Drug: TDV Liquid Formulation 2;   Drug: TDV IDT Lyophilized;   Drug: Placebo
68 Completed Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Intervention:
69 Unknown  Prospective Study of Infant Dengue
Condition: Dengue
Intervention:
70 Completed Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults
Condition: Dengue Fever
Interventions: Biological: rDEN4delta30-200,201;   Biological: Placebo
71 Completed Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: rDEN3∆30;   Biological: Placebo
72 Completed Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
Condition: Healthy
Interventions: Biological: DENVax;   Biological: Phosphate buffered saline
73 Completed Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
Conditions: Dengue Virus;   Dengue Fever;   Dengue Hemorrhagic Fever;   Dengue Diseases
Interventions: Biological: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero);   Biological: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero);   Biological: Tetravalent CYD-1,2,3,4 Dengue (Vero);   Biological: JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)
74 Completed International Research Consortium on Dengue Risk Assessment, Management, and Surveillance
Condition: Dengue Fever
Intervention: Other: Observation
75 Recruiting This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
Condition: Dengue
Intervention: Procedure: Blood sample collection
76 Recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
77 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
78 Completed Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV003;   Biological: rDEN2∆30-7169;   Biological: Placebo
79 Active, not recruiting Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
Condition: Healthy Volunteers
Interventions: Biological: Takeda's Tetravalent Dengue Vaccine Candidate;   Drug: TDV Placebo
80 Recruiting Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
Condition: Dengue Fever
Intervention: Other: case/control

First Page    Show previous page of results Previous Page (41-60) Studies Shown (61-80) Next Page (81-100) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.